The combination of axi-cel and rituximab showed high efficacy in refractory LBCL, with a 73% complete response rate and 88% overall response rate. Safety was favorable, with no new signals; 96% ...
Oncolytics also recently expanded its Scientific Advisory Board with globally recognized experts from Memorial Sloan Kettering Cancer Center and MD Anderson Cancer Center, positioning the company for ...
Detailed price information for Nurix Therapeutics Inc (NRIX-Q) from The Globe and Mail including charting and trades.
Dr. Ian Flinn explains in an interview with CURE how Lunsumio VELO (mosunetuzumab) works and its impact on patients with ...
GlobalData on MSN
ImmunityBio’s Anktiva shows success as combo treatment in NSCLC
Anktiva plus checkpoint inhibitor therapy demonstrated statistically significant immune restoration across two clinical ...
News Medical on MSN
Lund researchers create "recipe book" for reprogramming immune cells to fight disease
In order to reprogram readily available cells into specific immune cells that fight various diseases, one must know the ...
A toxin secreted by cholera bacteria can inhibit the growth of colorectal cancer without causing any measurable damage to the ...
News-Medical.Net on MSN
DLL3 on circulating tumor cells predicts tarlatamab success in lung cancer
A team led by investigators at the Mass General Brigham Cancer Institute has discovered that a particular marker on tumor ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback